Cellchorus Inc.
Houston, TX
- UEI
- LUF6ANBGK7F4
- CAGE
- 8V6F5
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5000 Gulf Fwy #118, Houston, TX 77023, USA
- Website
- cellchorus.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Functional signatures of post-infusion car t cells for early indication of patient response - 7. Project… | National Cancer Institute | $399,625 | |
| LF-timing: large-scale label-free profiling of cell-cell interactions - 7. Project summary/abstract there is a… | National Center for Advancing Translational Sciences | $3,628,024 | |
| Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing - abstract cell and… | National Center for Advancing Translational Sciences | $7,340,714 | |
| Sbir phase i: development of arrays to record dynamic interactions between single cells -the broader/commercial impact… | National Science Foundation | $274,988 | |
| Dynamic single-cell analysis instrument to evaluate immune cell function - 7. Project summary/abstract recent decades… | National Institute of General Medical Sciences | $4,849,016 |
About Cellchorus Inc.
Cellchorus Inc. is a Houston-based corporate entity specializing in advanced cell analysis technologies, with a focus on developing artificial intelligence-powered platforms for single-cell dynamic imaging and functional characterization. The company operates as a for-profit organization registered in SAM.gov and has demonstrated expertise in creating sophisticated imaging and computational technologies for biomedical research, particularly in the realm of cell therapy and immunological studies. Their core technology, called TIMING (Time-lapse Imaging Microscopy in Nanowell Grids), is an AI-driven platform designed to track and analyze individual cell behaviors with high-throughput capabilities.
The company has secured multiple federal grants from agencies including the National Cancer Institute, National Center for Advancing Translational Sciences, National Science Foundation, and National Institute of General Medical Sciences. These grants, ranging from approximately $399,625 to unspecified amounts, support the development of advanced cell analysis technologies with specific applications in cancer research, cell therapy manufacturing, and immune cell interaction studies. Cellchorus' projects focus on developing sophisticated analytical platforms that can provide detailed insights into cell dynamics, including tracking cell movements, interactions, killing behaviors, proliferative capacities, and metabolic activities. Their research aims to create tools that can help researchers and medical professionals better understand cellular performance, particularly in the context of emerging therapies like CAR T-cell treatments for cancers such as large B cell lymphoma. The grants support the company's efforts to create scalable, high-resolution imaging technologies that can provide unprecedented insights into cellular behavior at the single-cell level.
Quick answers
What is Cellchorus Inc.'s UEI?
Cellchorus Inc.'s Unique Entity ID (UEI) in SAM.gov is LUF6ANBGK7F4.
What is Cellchorus Inc.'s CAGE code?
Cellchorus Inc.'s CAGE code is 8V6F5.
Where is Cellchorus Inc. located?
Cellchorus Inc.'s physical address in SAM.gov is 5000 Gulf Fwy #118, Houston, TX 77023, USA.
Is Cellchorus Inc. registered in SAM.gov?
Yes. Cellchorus Inc.'s SAM.gov registration is active through January 7, 2027.
What is Cellchorus Inc.'s most recent federal award?
Cellchorus Inc.'s most recent federal grant award is Functional signatures of post-infusion car t cells for early indication of patient response - 7. Project… (R43CA298411), from National Cancer Institute, on September 1, 2025.
On GovTribe
See Cellchorus Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors